LINKER-MM1
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma (LINKER-MM1)
What will happen during the trial?
The study is looking at several other research questions, including:
- Side effects that may be experienced by people receiving linvoseltamab
- How linvoseltamab works in the body
- How much linvoseltamab is present in the blood
- How linvoseltamab may work to treat cancer
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 309 patients (estimated)
- Sponsors
- Regeneron Pharmaceuticals
- Tags
- Bispecific Antibody, CD3, B-Cell Maturation Antigen (BCMA)
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 1016
- NCT Identifier
- NCT03761108
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.